Histrelin Acetate

• CAT Number: I007208
• CAS Number: 220810-26-4
• Molecular Formula: C66H86N18O12
• Molecular Weight: 1323.5
• Purity: ≥95%
• Synonyms: Supprelin LA; Des-Gly10,His(Bzl)6,Pro-NHEt9)-LHRH
• Target: GnRH
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term or -20 °C for long term
• Related CAS: 76712-82-8(free base)
• InChIKey: OWAUGAMNPZHEOJ-YKZVIGSYSA-N
• SMILES: CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8.CC(=O)O

Histrelin acetate(CAT: I007208) is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH). It is commonly used as a medication for the treatment of hormone-dependent conditions such as prostate cancer, endometriosis, and precocious puberty. Histrelin acetate acts by continuously suppressing the production of sex hormones in the body, thereby reducing the growth and activity of hormone-sensitive tissues.

Reference

1: Crawford ED. A review of the use of histrelin acetate in the treatment of
prostate cancer. BJU Int. 2009 Mar;103 Suppl 2:14-22. doi:
10.1111/j.1464-410X.2009.08384.x. Review. PubMed PMID: 19228148.

2: Schlegel P. A review of the pharmacokinetic and pharmacological properties of
a once-yearly administered histrelin acetate implant in the treatment of prostate
cancer. BJU Int. 2009 Mar;103 Suppl 2:7-13. doi:
10.1111/j.1464-410X.2009.08383.x. Review. PubMed PMID: 19228147.